Page 33 - Read Online

Page 14 of 15 Feng et al. Hepatoma Res 2021;7:3 I http://dx.doi.org/10.20517/2394-5079.2020.107

delivery of oncolytic viruses. Biochim Biophys Acta 2008;1785:217-31.
49. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
50. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature
2006;441:101-5.
51. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015;14:642-62.
52. Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic virus-based immunotherapies for hepatocellular carcinoma. Mediators Inflamm
2017;2017:5198798.
53. Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic
adenovirus. Clin Cancer Res 2013;19:2734-44.
54. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer
2009;9:64-71.
55. Abdullahi S, Jäkel M, Behrend SJ, et al. A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the
treatment of hepatocellular carcinoma. J Virol 2018;92:e01386-18.
56. Zhang H, Li K, Lin Y, et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl
Med 2017;9:eaam7996.
57. Luo Y, Lin C, Ren W, et al. Intravenous injections of a rationally selected oncolytic herpes virus as a potent virotherapy for hepatocellular
carcinoma. Mol Ther Oncolytics 2019;15;153-65.
58. Chen A, Zhang Y, Meng G, et al. Oncolytic measles virus enhances antitumour responses of adoptive CD8(+)NKG2D(+) cells in
hepatocellular carcinoma treatment. Sci Rep 2017;7:5170.
59. Xie W, Hao J, Zhang K, et al. Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and
apoptosis promotion. Biochem Biophys Res Commun 2018;503:2758-63.
60. Nakatake R, Kaibori M, Nakamura Y, et al. Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.
Cancer Sci 2018;109:600-10.
61. El-Shemi AG, Ashshi AM, Oh E, et al. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first
evidence in preclinical hepatocellular carcinoma. Gene Ther 2018;25;54-65.
62. Zhang J, Lai W, Li Q, et al. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via
metastasis, apoptosis and autophagy in HCC models. Biochem Biophys Res Commun 2017;491;469-77.
63. Lv SQ, Ye ZL, Liu PY, et al. 11R-P53 and GM-CSF expressing oncolytic adenovirus target cancer stem cells with enhanced synergistic
activity. J Cancer 2017;8:199-206.
64. El-Shemi AG, Ashshi AM, Na Y, et al. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly
suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res
2016;35:74.
65. Ruf B, Berchtold S, Venturelli S, et al. Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine
virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Mol Ther Oncolytics 2015;2:15019.
66. Ady JW, Johnsen C, Mojica K, Heffner J, Love D, et al. Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently
kills hepatocellular carcinoma. Surgery 2015;158;331-8.
67. Ady JW, Heffner J, Mojica K, et al. Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant
hepatocellular carcinoma efficiently. Surgery 2014;156;263-9.
68. Lin WH, Yeh SH, Yang WJ, et al. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx
transgenic mice. Int J Cancer 2013;132:1451-62.
69. Wang J, Xu L, Zeng W, et al. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell
Int 2014;14:83.
70. Fu X, Rivera A, Tao L, et al. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol
Ther 2012;20:339-46.
71. Gentschev I, Müller M, Adelfinger M, et al. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the
oncolytic vaccinia virus strain GLV-1h68. PLoS One 2011;6:e22069.
72. Jin H, Lv S, Yang J, et al. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular
carcinoma cells. PLoS One 2011;6:e21307.
73. Lee JH, Roh MS, Lee YK, et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF
following intravenous administration in a rabbit tumor model. Cancer Gene Ther 2010;17:73-9.
74. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer
treatment: implications for virus design and delivery. Cancer Res 2003;63:1317-24.
75. Thorne SH, Hwang TH, O’Gorman WE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective
oncolytic poxvirus, JX-963. J Clin Invest 2007;117:3350-8.
76. Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus
expressing GM-CSF. Mol Ther 2006;14:361-70.
77. Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by
genetic pathways commonly activated in cancers. Mol Ther 2012;20:749-58.
78. Park B, Hwang T, Liu T, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer:
a phase I trial. Lancet Oncology 2008;9:533-42.